Your browser doesn't support javascript.
loading
How to Manage a Patient with Ocular Metastases?
Thariat, Juliette; Boudin, Laurys; Loria, Olivier; Nguyen, Anh-Minh; Kodjikian, Laurent; Mathis, Thibaud.
Afiliação
  • Thariat J; Laboratoire de Physique Corpusculaire IN2P3-CNRS UMR 6534 ARCHADE, Unicaen Université de Normandie, 6 bd du Maréchal Juin, 14050 Caen, France.
  • Boudin L; Service d'Oncologie, Hôpital d'Instruction des Armées Sainte Anne, 2 bd Sainte-Anne BP600, 83000 Toulon, France.
  • Loria O; Service d'Ophtalmologie, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, 103 Grand-rue de la Croix-Rousse, 69317 Lyon, France.
  • Nguyen AM; Laboratoire UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, 345 av. Gaston Berger, 69100 Villeurbanne, France.
  • Kodjikian L; Service d'Ophtalmologie, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, 103 Grand-rue de la Croix-Rousse, 69317 Lyon, France.
  • Mathis T; Service d'Ophtalmologie, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, 103 Grand-rue de la Croix-Rousse, 69317 Lyon, France.
Biomedicines ; 10(12)2022 Nov 25.
Article em En | MEDLINE | ID: mdl-36551800
ABSTRACT
Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5-10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect to the way systemic and local therapies should be selected in combination or sequentially in the personalized medical history of a patient. The challenges include tumor control, eye preservation, and the minimization of iatrogenic damage to sensitive tissues surrounding the tumor in order to preserve vision. These aims should further contribute to maintaining quality of life in patients with metastases. Many patients with choroidal metastases have systemic molecular treatment for their primary tumor. However, secondary resistance to systemic treatment is common and may ultimately be associated with cancer relapse, even after an initial response. Therefore, it makes sense to propose local treatment concomitantly or after systemic therapy to provide a more sustainable response. The aim of this review is to present current therapeutic strategies in ocular metastases and discuss how to tailor the treatment to a specific patient.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Biomedicines Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Biomedicines Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França